Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Reduce” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given a consensus recommendation of “Reduce” by the nine analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company.

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th.

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $7.25 on Friday. The company has a market cap of $28.49 billion, a PE ratio of -8.33 and a beta of 1.08. The firm’s 50 day moving average price is $7.75 and its 200-day moving average price is $7.52. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. Bayer Aktiengesellschaft has a 52-week low of $6.82 and a 52-week high of $11.71.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The firm had revenue of $12 billion during the quarter. Sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.